TY - JOUR
T1 - Failure mode and effects analysis in pharmaceutical research
AU - Inoue, Hirotaka
AU - Yamada, Shu
PY - 2010/10/19
Y1 - 2010/10/19
N2 - Purpose – Quality management tools such as failure mode and effects analysis (FMEA) have been implemented in various industries to improve quality. This report aims to demonstrate that FMEA can be applied as a performance improvement tool, based on case analysis of process improvement conducted for a drug discovery project. Design/methodology/approach – The main points of the proposed FMEA process include: inclusion of an interface that makes it easy to visualize complicated processes in pharmaceutical research; identification of undesirable effects to indicate process defects; and a quantitative estimate of the undesirable effects related to quality and efficiency. Findings – The effectiveness of the proposed FMEA process was evaluated based on in vivo screening/profiling during early drug discovery. The process targeted for improvement was visualized using a flow diagram. The undesirable effects identified included waiting, false operations, and errors in the decisionmaking and reporting processes. The most serious flaws, determined by risk priority numbers for each category, were waiting and false operations. Originality/value – The effectiveness of the proposed FMEA was demonstrated by applying the analysis to another in vivo profiling process. Quantitative evaluation of the undesirable effects determined that they were reasonable. This provides a benefit for scientists seeking to improve the drug discovery process.
AB - Purpose – Quality management tools such as failure mode and effects analysis (FMEA) have been implemented in various industries to improve quality. This report aims to demonstrate that FMEA can be applied as a performance improvement tool, based on case analysis of process improvement conducted for a drug discovery project. Design/methodology/approach – The main points of the proposed FMEA process include: inclusion of an interface that makes it easy to visualize complicated processes in pharmaceutical research; identification of undesirable effects to indicate process defects; and a quantitative estimate of the undesirable effects related to quality and efficiency. Findings – The effectiveness of the proposed FMEA process was evaluated based on in vivo screening/profiling during early drug discovery. The process targeted for improvement was visualized using a flow diagram. The undesirable effects identified included waiting, false operations, and errors in the decisionmaking and reporting processes. The most serious flaws, determined by risk priority numbers for each category, were waiting and false operations. Originality/value – The effectiveness of the proposed FMEA was demonstrated by applying the analysis to another in vivo profiling process. Quantitative evaluation of the undesirable effects determined that they were reasonable. This provides a benefit for scientists seeking to improve the drug discovery process.
KW - Failure mode and effects analysis
KW - Pharmaceuticals industry
KW - Research
UR - http://www.scopus.com/inward/record.url?scp=84986135999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986135999&partnerID=8YFLogxK
U2 - 10.1108/17566691011090080
DO - 10.1108/17566691011090080
M3 - Article
AN - SCOPUS:84986135999
VL - 2
SP - 369
EP - 382
JO - International Journal of Quality and Service Sciences
JF - International Journal of Quality and Service Sciences
SN - 1756-669X
IS - 3
ER -